StockData
Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (IOVA) bonds

IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.48−0.05 (-0.66%)

Close on Nov 18, 2026Market cap $3.39BP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Iovance Biotherapeutics reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Notes and loans outstanding

As tagged in Iovance Biotherapeutics's 10-K for the period ended Jan 26, 2021

IssueCouponAmount issued
Job Creation Loan0.00%$1.00M

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-K.

See a number that looks wrong?